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Background: Severe falciparum malaria is associated with considerable rates of mortality, despite the administration
of appropriate anti-malarial treatment. Since overall survival is associated with total parasite biomass, blood
exchange transfusion has been proposed as a potential method to rapidly reduce peripheral parasitaemia. However,
current evidence suggests that this treatment modality may not improve outcome. Automated red blood cell
exchange (also referred to as “erythrocytapheresis”) has been advocated as an alternative method to rapidly remove
parasites from circulating blood without affecting patients’ volume and electrolyte status. However, only limited
evidence from case reports and case series is available for this adjunctive treatment. This retrospective cohort study
describes the use of automated red blood cell exchange for the treatment of severe malaria at the Medical
University of Vienna.
Methods: Epidemiologic data for imported malaria cases in Austria are reported and data of patients treated for
malaria at the General Hospital/Medical University of Vienna were extracted from electronic hospital records.
Results: Between 2000 and 2010, 146 patients were hospitalized at the Medical University of Vienna due to malaria
and 16 of those were classified as severe malaria cases. Eleven patients of this cohort were potentially eligible for an
adjunctive treatment with automated red blood cell exchange. Five patients eventually underwent this procedure
within a period of seven hours (range: 3–19 hours) after hospital admission. Six patients did not undergo this
adjunctive treatment following the decision of the treating physician. The procedure was well tolerated in all cases
and rapid reduction in parasite counts was achieved without occurrence of haemodynamic complications. One
patient died within seven days, whereas four patients survived without any sequelae.
Discussion and conclusion: Automated red blood cell exchange was a safe and efficient procedure to rapidly clear
peripheral parasitaemia. Whether the fast reduction in parasite biomass may ultimately improve patient survival
remains however unclear. Randomized controlled trials are needed to conclusively appreciate the value of this
adjunctive treatment.
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Severe malaria, caused by Plasmodium falciparum, is
associated with high mortality despite appropriate
management at intensive care facilities. Few therapeutic
interventions have been shown effective to improve
survival, including parenteral artesunate, mechanical
ventilation and renal replacement therapy [1-6]. Other
adjunctive treatments (e.g. application of corticosteroids
to reduce cerebral oedema, anticonvulsive drugs in cere-
bral malaria or antipyretics.) did not improve patient’s
outcome, some of which were even associated with
increased rates of sequelae and death [7-9].
Whole blood exchange transfusion has been proposed
as a method to rapidly reduce parasite biomass [10]. A
meta-analysis of eight case–control studies including 279
patients demonstrated that whole blood exchange trans-
fusion was not superior to parenteral anti-malarial
chemotherapy alone, discouraging the use of this
adjunctive treatment [11].
Automated red blood cell (RBC) exchange is a tech-
nique that may potentially overcome problems associated
with whole blood exchange [12-16]. With this procedure,
RBCs are separated automatically from the patient’s
whole blood, while plasma, platelets and white blood
cells are retained. This procedure is known to be better
tolerated in various indications compared to whole blood
exchange transfusion with regards to volume alterations,
coagulation and electrolyte disturbances, and susceptibil-
ity to infection [17-19]. RBC exchange has been success-
fully used in patients with sickle cell crises [20] and has
been advocated as adjunctive treatment option for severe
malaria. First case reports and case series have supported
the use of automated RBC exchange and several national
guidelines acknowledge the therapeutic potential for
selected patients [21-25]. However, firm evidence for
RBC exchange derived from randomized controlled clin-
ical trials is still lacking. In the absence of such informa-
tion, more data from case series and patient cohorts at
different institutions are needed to increase the level of
evidence. This study reports the use of RBC exchange as
an adjunctive treatment for severe falciparum malaria in
a cohort of patients treated at the Medical University of
Vienna in Austria between 2000 and 2010.
Methods
Patient selection
Epidemiologic data on the number of malaria cases in
Austria were obtained from mandatory reports of notifi-
able infectious diseases. According to Austrian law, all
suspected, confirmed or fatal cases of malaria have to be
reported to public authorities and the federal ministry of
health, respectively. A list of all patients treated for
malaria at the Medical University of Vienna was obtained
from an automated database search of the institution’selectronic patient record system. Individual patient data
were extracted from electronic hospital records. All
clinical and laboratory data associated with the auto-
mated RBC exchange were obtained from patient record
forms at the Department of Bloodgroup Serology and
Transfusion Medicine. Records were entered into an elec-
tronic database. The study was approved by the Ethics
Committee of the Medical University of Vienna. The
World Health Organization (WHO) criteria for severe
malaria [25] were employed for classification of severity
of malaria cases. Patients received anti-malarial chemo-
therapy according to standard treatment guidelines based
on randomized controlled trials, irrespective of the
commencement of RBC exchange, with parenteral quin-
ine and clindamycin [1,6,24,26].
Automated RBC exchange
Automated RBC exchange was conducted by dedicated
personnel of the Department of Bloodgroup Serology
and Transfusion Medicine as an adjunctive treatment to
anti-malarial chemotherapy. According to institutional
consensus guidelines, patients diagnosed with acute P.
falciparum malaria demonstrating hyperparasitaemia
defined as >10 % infected erythrocytes and single or
multi-organ failure were eligible for RBC exchange in
addition to routine anti-malarial drug administration.
For further classification, subsequent assessment of treat-
ment responses and parasitaemia, Giemsa-stained thick
and thin blood smears were prepared using standard
protocols at admission, before and after RBC exchange,
and regularly until specimen were free of parasites.
Results
Patient characteristics of malaria cases in Austria between
2000 and 2010
Six hundred fifteen cases of malaria were reported to
federal agencies in Austria between January 2000 and
December 2010. Almost half of them (44 %, n = 272)
occurred in the capital Vienna [27]. One hundred forty
six patients (135 adults and 11 children) received
in-patient treatment for malaria at the Medical University
of Vienna during that time. Demographic data and
patient characteristics are summarized in Figure 1. The
majority (n = 111; 76 %) of patients were male and Africa
was the most common place of infection (Nigeria n = 30;
20.5 %, Ghana n = 19; 13 % and Kenya n = 13; 8.9 %).
Peripheral thick or thin blood smears showed acute
P. falciparum infection in 107 cases (73.3 %), four of
which were mixed infections with Plasmodium vivax
(n = 2) or Plasmodium ovale (n = 2). Sixteen (11 %)
patients suffered from severe malaria according to WHO
criteria [1]. Thirteen (8.9 %) of those patients (Table 1)
were treated at intensive care units (ICU) whereas the
remaining three patients with severe malaria showed
Patients hospitalized at Vienna 
General Hospital2 (n=146)
Malaria cases1 in Austria 
(n=615)
Malaria cases1 in Vienna 
(n=272)
Gender:
• Male (n=111; 76%)
• Female (n=35; 24%)
Age:
• Median: 34 years
• Min: 1 year




• Africa (n=118; 80%)
• Asia (n=13; 9%)
• Latin America (n=12; 8%)
• Not determined (n=3)
Plasmodium species:
• P. falciparum  (n=103; 71%)
• P. vivax  (n=28; 19%)
• P. ovale (n=7; 5%)
• P. malariae  (n=1; <1%)
• Mixed3 (n=4)
• Not determined (n=3)
Days of hospitalisation:
• Median: 4 days
• Min: 1 day
• Max: 124 days 
Patients with severe malaria 
(n=16) 
Type of parasite:
• P. falciparum (n=15)
• Mixed P. falciparum and 
P. vivax  
Treated at Intensive Care Unit 
(n=13)4
Adjunctive automated RBC 
exchange (n=5)
Conventional therapy w/o 
automated RBC exchange 
(n=6)
Eligible for automated RBC 
exchange (n=11)
Table 1
Figure 1 Flow diagram of malaria cases in Austria and the Medical University of Vienna.1 Reported to federal agencies; 2 According to
the electronic patient record system; 3 Plasmodium falciparum and Plasmodium ovale (n = 2), Plasmodium falciparum and Plasmodium vivax (n = 2);
4 Three patients did not require ICU admission (see text); ICU: intensive care unit; RBC: red blood cell.
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ation of therapy and were not transferred to an ICU.
Patients presenting with severe Plasmodium
falciparum infection
Fifteen patients fulfilling criteria for severe malaria had
P. falciparum mono-infection and one patient showed
mixed infection of P. falciparum and P. vivax. Intraven-
ous anti-malarial chemotherapy (quinine dihydrochloride
and clindamycin; 10 mg/kg every eighth hour with a
loading dose of 20 mg/kg and 5–10 mg/kg twice daily,respectively) was initiated immediately after diagnosis.
Electrocardiography, continuous blood glucose measure-
ments and frequent clinical assessments during infusion
ensured adequate monitoring for quinine related side
effects. Eleven patients qualified for adjunctive RBC ex-
change according to the institution’s guidelines. Eventu-
ally, five adult patients received automated RBC
exchange (Table 1). Six patients, though eligible, received
anti-malarial chemotherapy alone following the decision
of the treating physician. Since this was not a rando-
mized controlled trial, the two treatment groups were
Table 1 Characteristics of patients with severe Plasmodium falciparum treated at the ICU with conventional treatment
alone or with adjunctive automated RBC exchange
Conventional treatment (n = 8) Adjunct RBC exchange (n = 5)
Median Age in years (range) 43 (1–64) 54 (30–71)
Sex (Male / female) 7 / 1 4 / 1
Median days on ICU (range) 6.5 (2–45) 7 (2–81)
Ethnicity Caucasian 5 4
African 2 -
Middle East 1 1
Area of Infection (n) Africa 7 5
Other 1 (Nicaragua) -
Prophylaxis (n) Yes - -
No 5 4
Not determined 3 1
Cerebral malaria (n) 6 (75 %) 3 (60 %)
Parasitaemia >10 % (n) 6 (75 %) 5 (100 %)
Mechanical ventilation (n) 5 (63 %) 2 (40 %)
Acute renal failure1 (n) 4 (50 %) 2 (40 %)
Norepinephrine demand (n) 4 (50 %) 4 (80 %)
Baseline laboratory parameters
(median, range)
Haemoglobin (g/dl) 11.45 (4.9-16.1) 8.3 (5.7-12.6)
Platelets (G/l) 28.5 (14–50) 46 (15–82)
Lactate (mmol/l) 3.1 (2.2-5.02) 5.1 (2.3-12.9)
LDH (U/l) 779 (278–1392) 692.5 (340–1848)
Blood glucose (mg/dl) 123 (73–226) 85 (82–267)
Median APACHE II score (range) 17 (10–29) 26 (16–32)
Median SAPS II (range) 45 (34–93) 61 (39–78)
Treatment Quinine + clindamycin Quinine + clindamycin3
Total number of RBC exchanges (n) 0 7
Patients with 1 RBC exchange 0 3
Patients with 2 RBC exchanges 0 2
Adverse Events (moderate or sever intensity) 4 4
Adverse events related to RBC exchange - -
Unrelated adverse events ARDS (n = 2) ARDS (n = 1)
Septic shock (n = 1) VAP (n = 1)
Retinopathy (n = 1) Fungal sepsis (n = 1)
Increase of intracranial pressure (n = 1) DIC (n = 1)
Pneumonia (n = 2) Death (n = 1)
Delirium (n = 2)
DIC (n = 2)
1 Requiring renal replacement therapy; 2 Calculated after ICU admission within 24 hours; only applicable to adults; 3 Two patients initially received intra-rectal
artesunate prior to referral; APACHE: acute physiology and chronic health evaluation; ARDS: acute respiratory distress; DIC: disseminated intravascular coagulation;
ICU: intensive care unit; LDH: lactate dehydrogenase; RBC: red blood cell; SAPS: simplified acute physiology score; VAP: ventilator associated pneumonia.
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treated with adjunctive RBC exchange showed more
advanced disease as evidenced by a higher median
APACHE II score than patients treated with anti-malarial
chemotherapy alone (26 versus 17; Table 1).
Eight of 13 patients with severe P. falciparum infection
who were admitted to the ICU and treated with anti-
malarial chemotherapy alone remained in hospital for amedian of 24 days (range, 9–70) (Table 1). All but one
patient had recently visited malaria endemic regions in
Africa, five had not taken adequate anti-malarial chemo-
prophylaxis and three were unable to provide information
about previous chemoprophylaxis. During the course of
treatment, four patients developed acute renal failure and
underwent haemodialysis. Furthermore, four patients
required intermittent norepinephrine administration to
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opathy and increased intracranial pressure were each
observed in one individual. One patient experienced
acute respiratory distress syndrome (ARDS) and pro-
gressed to septic shock during recovery phase. However,
all eight patients survived without clinical sequelae.
Patients treated with adjunctive automated RBC exchange
Characteristics and clinical features of patients undergo-
ing automated red blood cell exchange are shown in
Table 1. All patients had recently visited malaria endemic
regions in Africa, four had not taken adequate anti-
malarial chemoprophylaxis and one patient was unable to
provide information. RBC exchange was initiated within a
median of seven hours (range, 3–19 hours) after first
contact with a healthcare professional at the Medical
University of Vienna. All five patients received leukocyte
depleted, fully cross-matched packed red blood cells.
For RBC exchange, the COM.TECW (Fresenius, Bad
Homburg) cell separator was used in the first patient
(in 2001), whereas the COBEW Spectra apheresis system
(CaridianBCT, Lakewood) was used in the other cases.
RBC exchange was tolerated well without haemodynamic
alterations or other side effects. During the apheresis
procedure, a median 10 (range, 8–14) units of packed
RBCs were necessary to replace 3068 ml (range, 2417–
4591 ml) of potentially infected RBCs. RBC exchanges
led to a rapid decrease in parasite counts to marginal
levels (undetectable or <2 % infected RBCs) in peripheral
blood smears after the first apheresis cycle in three
patients and after a second cycle in the remaining two,
respectively. Three patients experienced rapid clinical
improvement and had an uncomplicated recovery with-
out any sequelae or persistent disability. In two of these
patients initial norepinephrine support was required to
maintain a mean arterial blood pressure >60 mmHg and
in another patient acute renal failure necessitated the use
of haemodialysis. One patient developed cerebral malaria
with significant neurological deficit (Glasgow Coma Scale
13), but fully regained consciousness without signs of
persistent neurologic damage. One patient died eight
days after admission and RBC exchange (APACHE II
score at admission: 32). In this case, the delay of medical
consultation following a febrile illness in Kenya led to
unarousable coma during the patient’s return flight.
When arriving at the ICU the patient had developed fully
constricted, non-reactive pinpoint pupils and massive
cerebral oedema (Glasgow Coma Scale 3). Another
patient treated with automated RBC exchange had a
prolonged and complicated recovery phase with renal
failure, ARDS, ventilation associated pneumonia and
fungal sepsis. Gradually, haemodialysis and mechanical
ventilation could be discontinued after kidney and
respiratory functions improved. Despite generalizedweakness due to long term ICU admission, the patient
did not develop persistent neurologic impairment. After
81 days of intensive care and 127 days admission in hos-
pital, this patient could be discharged and transferred to
a rehabilitation facility.
Discussion
This study describes a cohort of patients undergoing
RBC exchange in a tertiary health care institution in
Austria. Out of 146 patients treated for malaria at the
Medical University of Vienna, 13 were treated at an ICU
department. Eleven of them fulfilled institutional criteria
to consider RBC exchange, but only five patients were
actually treated with automated RBC exchange in a
ten-year period. This constitutes less than half of the
patients (45 %) who were potentially eligible according
to institution guidelines [24]. This discrepancy is most
likely explained by logistical constraints of automated
RBC exchange rather than by medical contraindications.
Challenges include rapid transfer of patients to specia-
lized medical centres, quick and reliable blood smear
assessment, diagnosis by experienced physicians and
established collaborations between infectious disease
departments, departments for Transfusion Medicine, and
the ICU. Furthermore, due to the lack of high quality
evidence for automated RBC exchange and the question-
able benefit of whole blood exchange [11], some physi-
cians may opt against the use of this adjunctive treatment
in severe malaria or may consider it too late for any
potential benefit. A well-organized interdisciplinary
approach involving staff of the departments of infectious
diseases, ICU, and Transfusion Medicine is needed to
address these logistical difficulties in a timely manner and
encourage physicians to consider automated RBC
exchange as an adjunctive treatment option.
Automated RBC exchange was commenced within an
acceptable time period and the procedure was well toler-
ated without any signs and symptoms of clinical deterior-
ation, electrolyte disturbances or bleeding complications.
The efficacy of physical removal of parasites was shown
by rapid clearance of peripheral parasitaemia. Despite
the exchange volume of approximately 1–1.5 times of
patients total RBC pool, apheresis did not lead to
problems in fluid overload and haemodynamic distress, a
phenomenon which was more frequently observed in
patients undergoing whole blood exchange transfusion
[17-19]. Moreover, during or shortly after automated
RBC exchange no specific medical intervention became
necessary to maintain haemodynamic and respiratory
stability. The occurrence of pneumonia and subsequent
lung failure in the patient with prolonged recovery was
related to mechanical ventilation. Based on the clinical
characteristics and the time course a causal association
of this complication with RBC exchange was deemed
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tion of anti-malarial treatment, this patient experienced
fungal sepsis, which was again a complication of
prolonged hospitalization at an ICU. One patient in the
adjunctive treatment group presented with advanced
cerebral malaria and died at the ICU.
In summary, one out of five patients treated with auto-
mated RBC exchange died whereas all eight patients in the
control group survived in this retrospective cohort study
(Table 1). However, no direct comparison of survival
rates between groups is justified since the absence of
randomization led to preferential inclusion of patients with
more advanced diseases in the RBC exchange group than
in the conventional treatment arm as evidenced by the
APACHE II score and lactate levels (Table 1).
Automated RBC exchange has been shown to be a safe
method to rapidly reduce parasitaemia in critical ill
patients. Since high-quality evidence from randomized
controlled trials is missing, a final judgement on the risk
benefit ratio of this adjunctive treatment for severe
malaria is not possible to date. Although total biomass of
parasites has been shown to correlate with severity of
falciparum malaria [28,29], it remains unclear whether
physical removal of parasites can improve patient’s
outcome. However, it may be argued that rapid reduction
of parasitaemia may benefit most patient populations at
highest risk for adverse outcome including non-immune
travellers and people living in regions of unstable malaria
transmission [11,30]. Importantly, this risk benefit
balance may depend on the employed anti-malarial drug
and its speed of action. Whereas artemisinins show rapid
parasite reduction in most endemic areas, quinine and
clindamycin have a significantly slower onset of activity
[2,6,26,31,32]. However, parasite clearance times of arte-
misinin derivatives are dramatically prolonged in regions
of South East Asia harbouring artemisinin resistant para-
site strains, indicating again a potential shift in the risk
benefit ratio of this potential adjunctive treatment in
different regions of the world [33,34].
Limitations of this report include most importantly the
retrospective study design since this does not guarantee
comparability of patient groups in the absence of
randomization and unified consistent definitions in the
malaria patients’ general care (e.g indications for respira-
tory support, ventilation or renal replacement therapy may
have slightly varied within ten years and between different
intensive care facilities). Improving the level of evidence is
therefore important; however the conduction of prospect-
ive studies evaluating this intervention is inherently diffi-
cult since high transmission regions often lack resources
for purchasing and maintenance of equipment and the
availability of safe blood products. Resource rich regions
on the other hand generally do not have adequate numbers
of patients with this condition. It is, therefore, likely thatcohort studies will remain the main source of evidence in
the near future.Conclusion and outlook
Whereas the reported experience with automated RBC
exchange is comparable to previous case reports
[12-17], the reporting of patient cohorts puts this
adjunctive treatment in perspective by providing infor-
mation about the proportion of patients undergoing this
procedure at the Medical University of Vienna. Since
randomized controlled trials are unlikely to be con-
ducted in the near future, further cohort studies are the
best way forward to increase the still limited knowledge
and experience with this adjunctive treatment at this
stage. This will allow to gradually increasing the level of
evidence and will ultimately help to determine whether
and which patient populations may benefit from this
adjunctive treatment.
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